Cangrelor vs. Standard Therapy to Achieve Optimal Management of Platelet Inhibition

Oct 10, 2018   |  Anthony A. Bavry, MD,MPH,FACC

Clinical Trial

The CHAMPION PHOENIX trial showed that the use of cangrelor reduced early ischemic events after PCI, including stent thrombosis, compared with clopidogrel.

Clinical Topics: Anticoagulation Management, Cardiovascular Care Team, Heart Failure and Cardiomyopathies, Invasive Cardiovascular Angiography and Intervention, Stable Ischemic Heart Disease, Vascular Medicine, Atherosclerotic Disease (CAD/PAD), Interventions and Coronary Artery Disease, Interventions and Vascular Medicine, Chronic Angina

Keywords: Coronary Artery Disease, Myocardial Infarction, Stroke, Ischemic Attack, Transient, Angina, Stable, Drug-Eluting Stents, Heparin, Peripheral Arterial Disease, Ticlopidine, Piperazines, Dyspnea, Purinergic P2Y Receptor Antagonists, Percutaneous Coronary Intervention, Thrombosis, Diabetes Mellitus, Platelet Glycoprotein GPIIb-IIIa Complex, ESC Congress

The Use of Anticoagulants in Peripheral Arterial Disease

Aug 20, 2014   |  Antonio Gutierrez, MD

Expert Analysis

The Centers for Disease Control and Prevention estimates that approximately 8 million Americans have peripheral arterial disease (PAD).1 Although a number of disease processes can cause PAD, the most common etiology is atherosclerosis. An...

Clinical Topics: Anticoagulation Management, Cardiovascular Care Team, Prevention, Vascular Medicine, Atherosclerotic Disease (CAD/PAD)

Keywords: Anticoagulants, Aspirin, Atherosclerosis, Centers for Disease Control and Prevention, U.S., Cost of Illness, Myocardial Infarction, Peripheral Arterial Disease, Secondary Prevention, Stroke, Ticlopidine